Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2009
 

or

 

[   ] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from       to      

 


 

Commission File Number: 000-31979

 


 

Array BioPharma Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

84-1460811

(State or Other Jurisdiction of
 Incorporation or Organization)

 

(I.R.S. Employer Identification No.)

 

 

 

3200 Walnut Street, Boulder, CO

 

80301

(Address of Principal Executive Offices)

 

(Zip Code)

 

(303) 381-6600

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes o  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer o        Accelerated Filer x

Non-Accelerated Filer o Smaller Reporting Company o

(do not check if smaller reporting company)

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

 

As of January 28, 2010, the registrant had 50,575,126 shares of common stock outstanding.

 

 



Table of Contents

 

ARRAY BIOPHARMA INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2009

TABLE OF CONTENTS

 

 

 

Page No.

 

 

 

PART I

FINANCIAL INFORMATION

1

Item 1.

Condensed Financial Statements (unaudited)

1

 

 

 

 

Condensed Balance Sheets as of December 31, 2009 and June 30, 2009

1

 

Condensed Statements of Operations and Comprehensive Loss for the three and six months ended December 31, 2009 and 2008

2

 

Condensed Statement of Stockholders’ Deficit for the six months ended December 31, 2009

3

 

Condensed Statements of Cash Flows for the six months ended December 31, 2009 and 2008

4

 

Notes to the Unaudited Condensed Financial Statements

5

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

41

Item 4.

Controls and Procedures

42

 

 

 

PART II

OTHER INFORMATION

 

Item 1.

Legal Proceedings

44

Item 1A.

Risk Factors

44

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

48

Item 3.

Defaults Upon Senior Securities

48

Item 4.

Submission of Matters to a Vote of Security Holders

48

Item 5.

Other Information

48

Item 6.

Exhibits

49

 

 

 

SIGNATURES

50

 

 

 

EXHIBIT INDEX

 

Certification of CEO Pursuant to Section 302

51

Certification of CFO Pursuant to Section 302

53

Certification of CEO and CFO Pursuant to Section 906

55

 



Table of Contents

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. CONDENSED FINANCIAL STATEMENTS

ARRAY BIOPHARMA INC.

Condensed Balance Sheets

(Amounts in Thousands, Except Share and Per Share Amounts)

(Unaudited)

 

 

 

December 31,

 

June 30,

 

 

2009

 

2009

 

 

 

 

 

ASSETS

 

 

 

 

Current assets

 

 

 

 

Cash and cash equivalents

 

  $

97,754

 

  $

33,202

Marketable securities

 

270

 

7,296

Prepaid expenses and other current assets

 

4,322

 

4,419

Total current assets

 

102,346

 

44,917

 

 

 

 

 

Long-term assets

 

 

 

 

Marketable securities

 

17,332

 

16,990

Property and equipment, net

 

23,964

 

26,498

Other long-term assets

 

3,391

 

6,650

Total long-term assets

 

44,687

 

50,138

Total assets

 

  $

147,033

 

  $

95,055

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

Current liabilities

 

 

 

 

Accounts payable and other accrued expenses

 

  $

7,556

 

  $

8,421

Accrued outsourcing costs

 

5,018

 

4,759

Accrued compensation and benefits

 

5,393

 

7,848

Deferred rent

 

3,107

 

3,034

Deferred revenue

 

40,634

 

11,233

Current portion of long-term debt

 

15,000

 

15,000

Total current liabilities

 

76,708

 

50,295

 

 

 

 

 

Long-term liabilities

 

 

 

 

Deferred rent

 

19,894

 

21,481

Deferred revenue

 

51,762

 

28,340

Long-term debt, net

 

94,701

 

68,170

Derivative liabilities

 

857

 

-

Other long-term liability

 

703

 

470

Total long-term liabilities

 

167,917

 

118,461

Total liabilities

 

244,625

 

168,756

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

Stockholders’ deficit

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding

 

-

 

-

Common stock, $0.001 par value; 120,000,000 shares authorized; 50,565,126 and 48,125,776 shares issued and outstanding, as of December 31, 2009 and June 30, 2009, respectively

 

51

 

48

Additional paid-in capital

 

320,666

 

312,349

Warrants

 

36,296

 

23,869

Accumulated other comprehesive income

 

5,222

 

3,234

Accumulated deficit

 

(459,827)

 

(413,201)

Total stockholders’ deficit

 

(97,592)

 

(73,701)

Total liabilities and stockholders’ deficit

 

  $

147,033

 

  $

95,055

 

The accompanying notes are an integral part of these condensed financial statements.

 

1



Table of Contents

 

ARRAY BIOPHARMA INC.

Condensed Statements of Operations and Comprehensive Loss

(Amounts in Thousands, Except Per Share Data)

(Unaudited)

 

 

 

Three Months Ended
December 31,

 

Six Months Ended
December 31,

 

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

 

 

 

Collaboration revenue

 

  $

4,434

 

  $

5,041

 

  $

9,478

 

  $

9,278

 

License and milestone revenue

 

5,210

 

2,648

 

8,056

 

4,158

 

Total revenue

 

9,644

 

7,689

 

17,534

 

13,436

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

Cost of revenue

 

5,235

 

5,063

 

11,157

 

10,183

 

Research and development for proprietary drug discovery

 

19,104

 

23,709

 

38,305

 

48,218

 

General and administrative

 

4,460

 

4,480

 

8,673

 

8,974

 

Total operating expenses

 

28,799

 

33,252

 

58,135

 

67,375

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

(19,155)

 

(25,563)

 

(40,601)

 

(53,939)

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

Impairment of marketable securities

 

-

 

(10,452)

 

(217)

 

(14,362)

 

Interest income

 

1,422

 

533

 

1,726

 

1,413

 

Interest expense

 

(4,092)

 

(2,336)

 

(7,534)

 

(4,616)

 

Total other income (expense)

 

(2,670)

 

(12,255)

 

(6,025)

 

(17,565)

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

(21,825)

 

(37,818)

 

(46,626)

 

(71,504)

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized gains and losses on marketable securities

 

93

 

(8)

 

1,988

 

1,949

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss

 

  $

(21,732)

 

  $

(37,826)

 

  $

(44,638)

 

  $

(69,555)

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - basic and diluted

 

49,405

 

47,605

 

48,771

 

47,589

 

 

 

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

  $

(0.44)

 

  $

(0.79)

 

  $

(0.96)

 

  $

(1.50)

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

2



Table of Contents

 

ARRAY BIOPHARMA INC.

Condensed Statement of Stockholders’ Deficit

(Amounts in Thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

Other

 

 

 

 

 

 

 

Preferred Stock

 

Common Stock

 

Paid-in

 

 

 

Comprehensive

 

Accumulated

 

 

 

 

 

Shares

 

Amounts

 

Shares

 

Amounts

 

Capital

 

Warrants

 

Income

 

Deficit

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of June 30, 2009

 

-

 

  $

-

 

48,125

 

  $

 48

 

  $

 312,349

 

  $

23,869

 

  $

 3,234

 

  $

 (413,201)

 

  $

 (73,701

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under stock option and employee stock purchase plans

 

-

 

-

 

683

 

1

 

1,096

 

-

 

-

 

-

 

1,097

 

Share-based compensation expense

 

-

 

-

 

-

 

-

 

2,996

 

-

 

-

 

-

 

2,996

 

Issuance of common stock for cash, net of offering costs

 

-

 

-

 

757

 

1

 

1,814

 

-

 

-

 

-

 

1,815

 

Issuance of common stock warrants

 

-

 

-

 

-

 

-

 

-

 

12,427

 

-

 

-

 

12,427

 

Payment of employee bonus with stock

 

-

 

-

 

1,000

 

1

 

2,411

 

-

 

-

 

-

 

2,412

 

Recognition of unrealized gain out of accumulated other comprehensive income to earnings

 

-

 

-

 

-

 

-

 

-

 

-

 

(394)

 

-

 

(394

)

Change in unrealized gain on

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

marketable securities

 

-

 

-

 

-

 

-

 

-

 

-

 

2,382

 

-

 

2,382

 

Net loss

 

-

 

-

 

-

 

-

 

-

 

-

 

-

 

(46,626)

 

(46,626

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of December 31, 2009

 

-

 

  $

 -

 

50,565

 

  $

 51

 

  $

 320,666

 

  $

36,296

 

  $

 5,222

 

  $

(459,827)

 

  $

 (97,592

)

 

The accompanying notes are an integral part of these condensed financial statements.

 

3



Table of Contents

 

ARRAY BIOPHARMA INC.

Condensed Statements of Cash Flows

(Amounts in Thousands)

(Unaudited)

 

 

 

Six Months Ended December 31,

 

 

 

2009

 

2008

 

 

 

 

 

 

 

Cash flows from operating activities

 

 

 

 

 

Net loss

 

  $

(46,626)

 

  $

(71,504

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

Depreciation and amortization expense

 

3,285

 

3,255

 

Non-cash interest expense for the Deerfield Credit Facility

 

3,363

 

3,489

 

Share-based compensation expense

 

2,996

 

2,964

 

Realized gain on marketable security

 

(1,165)

 

-

 

Impairment of marketable securities

 

217

 

14,362

 

Changes in operating assets and liabilities:

 

 

 

 

 

Prepaid expenses and other current assets

 

805

 

1,323

 

Accounts payable and other accrued expenses

 

(865)

 

474

 

Accrued outsourcing costs

 

259

 

(4,666

)

Accrued compensation and benefits

 

(43)

 

(2,178

)

Deferred rent

 

(1,514)

 

(1,289

)

Deferred revenue

 

52,823

 

2,592

 

Net cash provided by (used in) operating activities

 

13,535

 

(51,178

)

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

Purchases of property and equiment

 

(748)

 

(2,289

)

Purchases of marketable securities

 

-

 

(16,303

)

Proceeds from sales and maturities of marketable securities

 

9,853

 

41,750

 

Net cash provided by investing activities

 

9,105

 

23,158

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

Proceeds from exercise of stock options and shares issued under the employee stock purchase plan

 

1,097

 

1,585

 

Proceeds from the issuance of common stock for cash

 

2,121

 

-

 

Payment of offering costs

 

(306)

 

-

 

Proceeds from the issuance of long-term debt and warrants

 

40,000

 

40,000

 

Payment of transaction fee

 

(1,000)

 

(1,000

)

Net cash provided by financing activities

 

41,912

 

40,585

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

64,552

 

12,565

 

Cash and cash equivalents as of beginning of period

 

33,202

 

56,448

 

Cash and cash equivalents as of end of period

 

  $

97,754

 

  $

69,013

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

Cash paid for interest

 

  $

3,631

 

  $

1,023

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

4



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

NOTE 1 - OVERVIEW AND BASIS OF PRESENTATION

 

Organization

 

Array BioPharma Inc. (the “Company”) a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company’s proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins. In addition, leading pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across a broad range of therapeutic areas.

 

Basis of Presentation

 

The Company follows the accounting guidance outlined in the Financial Accounting Standards Board Codification.  The accompanying unaudited Condensed Financial Statements have been prepared without audit and do not include all of the disclosures required by the Financial Accounting Standards Board Codification guidelines, which have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) relating to requirements for interim reporting. The unaudited Condensed Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of management, are necessary to present fairly the financial position of the Company as of December 31, 2009, its results of operations for the three and six months ended December 31, 2009 and 2008, and its cash flows for the six months ended December 31, 2009 and 2008. Operating results for the three and six months ended December 31, 2009 are not necessarily indicative of the results that may be expected for the year ending June 30, 2010.

 

These unaudited Condensed Financial Statements should be read in conjunction with the Company’s audited Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2009 filed with the SEC on August 18, 2009.

 

Additionally, the Company has evaluated subsequent events occurring through the filing date of this Quarterly Report on Form 10-Q and has determined there were no subsequent events to record or disclose in this report.  Certain fiscal 2009 amounts have been reclassified to conform to the current year presentation. Specifically, Accounts Payable and Other Accrued Expenses were aggregated into one line item, Accounts Payable and Other Accrued Expenses, in the accompanying Condensed Balance Sheets.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S.”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Although management bases these estimates on historical data and other assumptions believed to be reasonable under the circumstances, actual results could differ significantly from these estimates.

 

The Company believes the accounting estimates having the most significant impact on its financial statements relate to (i) estimating the fair value of the Company’s auction rate securities (“ARS”); (ii) estimating accrued outsourcing costs for clinical trials and preclinical testing; (iii) estimating the fair value of the Company’s long-term debt that has associated warrants and embedded derivatives, which also requires separate valuation; and (iv) estimating the lives over which up-front payments and milestones from collaboration agreements are recognized.

 

5



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Liquidity

 

The Company has incurred operating losses and has an accumulated deficit primarily as a result of ongoing research and development spending. As of December 31, 2009, the Company had an accumulated deficit of $459.8 million. The Company had net losses of $21.8 million and $37.8 million for the three months ended December 31, 2009 and 2008, respectively, and $46.6 million and $71.5 million for the six months ended December 31, 2009 and 2008, respectively. The Company had net losses of $127.8 million, $96.3 million and $55.4 million for the fiscal years ended June 30, 2009, 2008 and 2007, respectively.

 

The Company has historically funded its operations through revenue from its collaborations and out-licensing transactions, the issuance of equity securities and through debt provided by its credit facilities. Until the Company can generate sufficient levels of cash from its operations, which the Company does not expect to achieve in the foreseeable future, the Company will continue to utilize its existing cash, cash equivalents and marketable securities that were generated primarily from these sources.

 

The Company currently uses approximately $21 million per quarter to fund its operations.  The Company believes that its existing cash, cash equivalents and marketable securities, excluding the value of the ARS it holds, will enable it to continue to fund its operations at this level for the next 12 months.  The Company is currently in active licensing discussions with a number of potential partners on select programs. In December 2009, the Company received a $60 million up front payment from Amgen Inc. under a Collaboration and License Agreement with them for the Company’s small-molecule glucokinase activator, AMG 151 / ARRY-403. The Company’s current plan contemplates the receipt of significant additional upfront payments from new collaboration or licensing deals in the next 12 months.  There can be no guarantee the Company will be successful in receiving such payments.  The Company also plans to satisfy its interest payment obligations under the credit facilities with Deerfield Private Design Fund, L.P. and Deerfield Private Design International Fund, L.P. (collectively “Deerfield”) either through the issuance of shares of common stock to Deerfield in accordance with the facility agreements with Deerfield discussed in Note 5 “Long-Term Debt – Deerfield Credit Facilities,” or with the proceeds from sales of its common stock pursuant to the Equity Distribution Agreement with Piper Jaffray & Co. discussed in Note 8 “Equity Distribution Agreement.”

 

If the Company is unable to obtain additional funding from these or other sources to the extent or when needed, it may be necessary to significantly reduce its current rate of spending through further reductions in staff and delaying, scaling back or stopping certain research and development programs. Insufficient funds may also require the Company to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to it or its stockholders than the Company would otherwise choose in order to obtain up-front license fees needed to fund its operations.

 

6



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Fair Value Measurements

 

The Company’s financial instruments are recognized and measured at fair value in the Company’s financial statements and mainly consist of cash and cash equivalents, marketable securities, long-term investments, trade receivables and payables, long-term debt, embedded derivatives associated with the long-term debt, and warrants. The Company uses different valuation techniques to measure the fair value of assets and liabilities, as discussed in more detail below. Fair value is defined as the price that would be received to sell the financial instruments in an orderly transaction between market participants at the measurement date. The Company uses a framework for measuring fair value based on a hierarchy that distinguishes sources of available information used in fair value measurements and categorizes them into three levels:

 

·

 

Level I:

 

Quoted prices in active markets for identical assets and liabilities.

·

 

Level II:

 

Observable inputs other than quoted prices in active markets for identical assets and liabilities.

·

 

Level III:

 

Unobservable inputs.

 

The Company discloses assets and liabilities measured at fair value based on their level in the hierarchy. Considerable judgment is required in interpreting market data to develop estimates of fair value for assets or liabilities for which there are no quoted prices in active markets, including ARS, warrants issued by the Company and the embedded derivatives associated with the Company’s long-term debt. The use of different assumptions and/or estimation methodologies may have a material effect on their estimated fair value. Accordingly, the fair value estimates disclosed by the Company may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.

 

The Company periodically reviews the realizability of each investment when impairment indicators exist with respect to the investment. If an other-than-temporary impairment of the value of an investment is deemed to exist, the carrying value of the investment is written down to its estimated fair value.

 

Cash and Cash Equivalents

 

Cash equivalents consist of short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of 90 days or less from the date of purchase and may consist of money market funds, taxable commercial paper, U.S. government agency obligations and corporate notes and bonds with high credit quality.

 

Marketable Securities

 

The Company has designated its marketable securities as of December 31, 2009 and June 30, 2009 as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying Condensed Balance Sheets. Marketable securities that are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying Condensed Balance Sheets.

 

Securities that are classified as available-for-sale are carried at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of Stockholders’ Deficit until their disposition. The Company reviews all available-for-sale securities each period to determine if it is more likely than not that they will remain available-for-sale based on the Company’s intent and ability to sell the security if it is required to do so. The amortized cost of debt securities in this category is adjusted for

 

7



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

amortization of premiums and accretion of discounts to maturity. Such amortization is included in Interest Income in the accompanying Condensed Statements of Operations and Comprehensive Loss. Realized gains and losses are reported in Interest Income and Interest Expense, respectively, in the accompanying Condensed Statements of Operations and Comprehensive Loss as incurred. Declines in value judged to be other-than-temporary are reported in Impairment of Marketable Securities in the accompanying Condensed Statements of Operations and Comprehensive Loss as recognized. The cost of securities sold is based on the specific identification method.

 

Under the fair value hierarchy, the Company’s ARS are measured using Level III, or unobservable inputs, as there is no active market for the securities. The most significant unobservable inputs used in this method are estimates of the amount of time until a liquidity event will occur and the discount rate, which incorporates estimates of credit risk and a liquidity premium (discount). Due to the inherent complexity in valuing these securities, the Company engaged a third-party valuation firm to perform an independent valuation of the ARS beginning with the first quarter of fiscal 2009 and continuing through the current fiscal quarter. While the Company believes that the estimates used in the fair value analysis are reasonable, a change in any of the assumptions underlying these estimates would result in different fair value estimates for the ARS and could result in additional adjustments to the ARS, either increasing or further decreasing their value, possibly by material amounts.

 

Property and Equipment

 

Property and equipment are stated at historical cost less accumulated depreciation and amortization. Additions and improvements are capitalized. Certain costs to internally develop software are also capitalized.  Maintenance and repairs are expensed as incurred.

 

Depreciation and amortization are computed on the straight-line method based on the following estimated useful lives:

 

Furniture and fixtures

 

7 years

Equipment

 

5 years

Computer hardware and software

 

3 years

 

The Company depreciates leasehold improvements associated with operating leases on a straight-line basis over the shorter of the expected useful life of the improvements or the reasonably assured term of the leases.

 

The carrying value for property and equipment is reviewed for impairment when events or changes in circumstances indicate the book value of the assets may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows from the use of the asset and its eventual disposition is less than its carrying amount.

 

Equity Investment

 

The Company may enter into collaboration and licensing agreements in which it receives an equity interest in consideration for all or a portion of up-front, license or other fees under the terms of the agreement. The Company reports the value of equity securities received from non-publicly traded companies in which it does not exercise a significant controlling interest at cost as Other Long-term Assets in the accompanying Condensed Balance Sheets. The Company monitors its investment for impairment at least annually and makes appropriate reductions in the carrying value if it is determined that an impairment has occurred, based primarily on the financial condition and near term prospects of the issuer.

 

8



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Accrued Outsourcing Costs

 

Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations, and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to it by the CROs, correspondence with the CROs and clinical site visits. The Company’s estimates depend on the timeliness and accuracy of the data provided by its CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives concerning changing circumstances, conditions or events that may affect such estimates.

 

Deferred Revenue

 

The Company records amounts received under its collaboration agreements, but not earned, as Deferred Revenue, which are then classified as current or long-term based on their expected recognition as revenue in the accompanying Condensed Balance Sheets.

 

Long-term Debt and Embedded Derivatives

 

The terms of the Company’s long-term debt are discussed in detail in Note 5 “Long-term Debt.” The accounting for these arrangements is complex and is based upon significant estimates by management. The Company reviews all debt agreements to determine the appropriate accounting treatment when the agreement is entered into, and reviews all amendments to determine if the changes require accounting for the amendment as a modification, or extinguishment and new debt.  The Company also reviews each long-term debt arrangement to determine if any feature of the debt requires bifurcation and/or separate valuation. These features include hybrid instruments, which are comprised of at least two components ((1) a debt host instrument and (2) one or more conversion features), warrants and other embedded derivatives, such as other rights of the debt holder.

 

The Company currently has two embedded derivatives related to its long-term debt with Deerfield.  The first is a variable interest rate structure that constitutes a liquidity-linked variable spread feature.  The second derivative is a significant transaction contingent put option relating to the ability of Deerfield to accelerate the repayment of the debt in the event of certain changes in control of the Company.  Collectively, they are referred to as the “Embedded Derivatives.”  Under the fair value hierarchy, the Company’s Embedded Derivatives are measured using Level III, or unobservable inputs as there is no active market for them. The fair value of the variable interest rate structure is based on the Company’s estimate of the probable effective interest rate over the term of the credit facilities. The fair value of the put option is based on the Company’s estimate of the probability that a change in control that triggers Deerfield’s right to accelerate the debt will occur.  With those inputs, the fair value of each Embedded Derivative is calculated as the difference between the fair value of the Deerfield credit facilities if the Embedded Derivatives are included, and the fair value of the Deerfield credit facilities if the Embedded Derivatives are excluded.  Due to the inherent complexity in valuing the Deerfield credit facilities and the Embedded Derivatives, the Company engaged a third-party valuation firm to perform the valuation as of July 31, 2009, September 30, 2009 and December 31, 2009.  The estimated fair value of the Embedded Derivatives was determined based on management’s judgment and assumptions. The use of different assumptions could result in significantly different estimated fair values.

 

The fair value of the Embedded Derivatives was initially recorded as Derivative Liabilities and as Debt Discount in the Company’s accompanying Condensed Balance Sheets. Any change in the value of the Embedded Derivatives is adjusted quarterly as appropriate and recorded to Derivative Liabilities in the

 

9



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Condensed Balance Sheets and Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.  The Debt Discount is being amortized from the draw date of July 31, 2009 to the end of the term of the Deerfield credit facilities using the effective interest method and recorded as Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

Warrants issued by the Company in connection with its long-term debt arrangements are reviewed to determine if they should be classified as liabilities or as equity.  All outstanding warrants issued by the Company have been classified as equity.  The Company values the warrants at issuance based on a Black-Scholes option pricing model and then allocates a portion of the proceeds under the debt to the warrants based upon their relative fair values.

 

Any transaction fees relating to the Company’s long-term debt arrangements are recorded as Other Long-Term Assets in the Condensed Balance Sheets and amortized to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss using the effective interest method over the term of the underlying debt agreement.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. The Company recognizes the amount of income taxes payable or refundable for the year as well as deferred tax assets and liabilities. Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying value and the tax basis of assets and liabilities, and, using enacted tax rates in effect for the year, reflect the expected effect these differences would have on taxable income. Valuation allowances are recorded to reduce the amount of deferred tax assets when, based upon available objective evidence, the expected reversal of temporary differences, and projections of future taxable income, management cannot conclude it is more likely than not that some or all of the deferred tax assets will be realized.

 

Operating Leases

 

The Company has negotiated certain landlord/tenant incentives, and rent holidays and escalations in the base price of rent payments under its operating leases. For purposes of determining the period over which these amounts are recognized or amortized, the initial term of an operating lease includes the “build-out” period of leases, where no rent payments are typically due under the terms of the lease, and includes additional terms pursuant to any options to extend the initial term if it is more likely than not that the Company will exercise such options. The Company recognizes rent holidays and rent escalations on a straight-line basis over the initial lease term. The landlord/tenant incentives are recorded as an increase to Deferred Rent in the accompanying Condensed Balance Sheets and amortized on a straight-line basis over the initial lease term. The Company has also entered into two sale-lease back transactions for its facilities in Boulder and Longmont, Colorado, where the consideration received from the landlord is recorded as increases to Deferred Rent in the accompanying Condensed Balance Sheets and amortized on a straight-line basis over the initial lease term. Deferred Rent balances are classified as short-term or long-term in the accompanying Condensed Balance Sheets based upon when reversal of the liability is expected to occur.

 

Share-Based Compensation

 

The Company uses the fair value method of accounting for share-based compensation arrangements which requires that compensation expense be recognized based on the grant date fair value of the arrangement. Share-based compensation arrangements include stock options granted under the Company’s Amended and Restated Stock Option and Incentive Plan (the “Option Plan”) and purchases of

 

10



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

common stock by its employees at a discount to the market price under the Company’s Employee Stock Purchase Plan (the “ESPP”).

 

The estimated fair value of stock options is based on the Black-Scholes option pricing model and is expensed on a straight-line basis over the vesting term. Compensation expense for stock options is reduced for estimated forfeitures, which are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense for purchases under the ESPP is recognized based on a Black-Scholes option pricing model that incorporates the estimated fair value of the common stock during each offering period and the percentage of the purchase discount.

 

Revenue Recognition

 

Most of the Company’s revenue is from research funding, up-front or license fees and milestone payments derived from discovering and developing drug candidates for the Company’s collaborators. The Company’s agreements with collaboration partners include fees based on contracted annual rates for full-time-equivalent employees working on a program, and may also include non-refundable license and up-front fees, non-refundable milestone payments that are triggered upon achievement of specific research or development goals, and future royalties on sales of products that result from the collaboration. A small portion of the Company’s revenue comes from the sale of compounds on a per-compound basis. The Company reports revenue for discovery, the sale of chemical compounds and the co-development of proprietary drug candidates that the Company out-licenses, as Collaboration Revenue. License and Milestone Revenue is combined and consists of the current period’s recognized up-front fees and ongoing milestone payments from collaborators.

 

The Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, Revenue Recognition (“SAB 104”), which establishes four criteria, each of which must be met, in order to recognize revenue related to the performance of services or the shipment of products. Revenue is recognized when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable, and (d) collectability is reasonably assured.

 

Collaboration agreements that include a combination of discovery research funding, up-front or license fees, milestone payments and/or royalties are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet the separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting in accordance with SAB 104.

 

The Company recognizes revenue from non-refundable up-front payments and license fees on a straight-line basis over the term of performance under the agreement, which is generally the estimated research term. These advance payments are deferred and recorded as Deferred Revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying Condensed Balance Sheets. When the performance period is not specifically identifiable from the agreement, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research term, the specific number of full-time-equivalent scientists working a defined number of hours per year at a stated price under the agreement, the existence, or likelihood of achievement, of development commitments, and other significant commitments of the Company.

 

The Company also has agreements that provide for milestone payments.  In certain cases, a portion of each milestone payment is recognized as revenue when the specific milestone is achieved based on the applicable percentage of the estimated research or development term that has elapsed to the total estimated research and/or development term.  In other cases, when the milestone payment finances future development obligations of the Company, the revenue is recognized on a straight-line basis over the estimated remaining development period.

 

11



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

The Company periodically reviews the expected performance periods under each of its agreements that provide for non-refundable up-front payments and license fees and milestone payments and the amortization periods are adjusted when appropriate.  Revenue recognition related to non-refundable license fees and up-front payments and to milestone payments could be accelerated in the event of early termination of programs or alternatively, decelerated, if programs are extended..

 

Cost of Revenue and Research and Development Expenses for Proprietary Drug Discovery

 

The Company incurs costs in connection with performing research and development activities which consist mainly of compensation, associated fringe benefits, share-based compensation, preclinical and clinical outsourcing costs and other collaboration-related costs, including supplies, small tools, facilities, depreciation, recruiting and relocation costs and other direct and indirect chemical handling and laboratory support costs. The Company allocates these costs between Cost of Revenue and Research and Development Expenses for Proprietary Drug Discovery based upon the respective time spent on each by its scientists on development conducted for its collaborators and for its internal proprietary programs. Cost of Revenue represents the costs associated with research and development, including preclinical and clinical trials, conducted by the Company for its collaborators. Research and Development Expenses for Proprietary Drug Discovery consist of direct and indirect costs related to specific proprietary programs and related to programs under collaboration agreements which the Company has concluded it is likely to retain the rights to. The Company does not bear any risk of failure for performing these activities and the payments are not contingent on the success or failure of the research program. Accordingly, the Company expenses these costs when incurred.

 

Where the Company’s collaboration agreements provide for it to conduct development of drug candidates, and for which the Company’s partner has an option to obtain the right to conduct further development and to commercialize a product, the Company attributes a portion of its research and development costs to Cost of Revenue based on the percentage of total programs under the agreement that the Company concludes is likely to be selected by the partner. These costs may not be incurred equally across all programs. In addition, the Company continually evaluates the progress of development activities under these agreements and if events or circumstances change in future periods that the Company reasonably believes would make it unlikely that a collaborator would exercise an option with respect to the same percentage of programs, the Company will adjust the allocation accordingly.

 

For example, the Company granted Celgene Corporation an option to select up to two of four programs developed under its collaboration agreement with Celgene and concluded that Celgene was likely to exercise its option with respect to two of the four programs. Accordingly, the Company reported costs associated with the Celgene collaboration as follows: 50% to Cost of Revenue, with the remaining 50% to Research and Development Expenses for Proprietary Drug Discovery. Celgene waived its rights with respect to one of the programs during the second quarter of fiscal 2010, at which time management determined that Celgene is likely to exercise its option to license one of the remaining three programs. Accordingly, beginning October 1, 2009, the Company began reporting costs associated with the Celgene collaboration as follows: 33.3% to Cost of Revenue, with the remaining 66.7% to Research and Development Expenses for Proprietary Drug Discovery.  See Note 4, “Deferred Revenue,” for further information about the Company’s collaboration with Celgene.

 

Net Loss per Share

 

Basic net loss per share is computed by dividing net loss for the period by the weighted averaged number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants issued related to the Company’s long-term debt. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. As a result of the Company’s net losses through the date of these Condensed Financial Statements, all potentially

 

12



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

 

Comprehensive Income (Loss)

 

The Company’s comprehensive income (loss) consists of the Company’s net loss and unrealized gains and losses on investments in available-for-sale marketable securities. The Company had no other sources of comprehensive income (loss) for the fiscal periods presented.

 

Recent Accounting Pronouncements

 

Collaborative Arrangements - In the first quarter of fiscal 2010, new guidance relating to the accounting practices and disclosures for collaborative arrangements became effective.  A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two (or more) parties who are both (a) active participants in the activity and (b) exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company’s collaboration agreements are determined to be collaborative arrangements, additional disclosures may be required by this guidance beginning with this Quarterly Report on Form 10-Q.  The Company determined that while certain agreements are collaborative arrangements, none of the current activities being performed under those arrangements would require a change to the accounting practices or disclosures made by the Company in its Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

 

Convertible Debt - In the first quarter of fiscal 2010, guidance relating to the accounting for “convertible debt” became effective. The Company determined that none of its credit facilities are considered “convertible debt” as defined under this accounting guidance and therefore this pronouncement had no impact on its financial statements and disclosures.

 

Fair Value Measurements - In August 2009, new literature was issued giving companies additional guidance relating to the fair value measurements and disclosures of liabilities.  The guidance was effective for the Company for the first quarter of fiscal 2010 and was adopted at that time.  The effect of the guidance is reflected in the accompanying Condensed Financial Statements.

 

Revenue Recognition for Multiple Deliverable Arrangements - In October 2009, new guidance was issued related to multiple-deliverable revenue arrangements that are effective for the Company prospectively for revenue arrangements entered into or materially modified subsequent to July 1, 2010.  The objective of this change is to address the accounting for multiple-deliverable arrangements to enable companies to account more easily for products or services (deliverables) separately rather than as a combined unit.  The Company is currently evaluating the impact of this guidance on its financial statements.

 

NOTE 2 – SEGMENTS, GEOGRAPHIC INFORMATION AND SIGNIFICANT COLLABORATORS

 

Segments

 

All operations of the Company are considered to be in one operating segment and, accordingly, no segment disclosures have been presented. The physical location of all of the Company’s equipment, leasehold improvements and other fixed assets is within the U.S.

 

13



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Geographic Information

 

All of the Company’s collaboration agreements are denominated in U.S. dollars.  The following table details revenue from collaborators by geographic area based on the country in which collaborators are located or the ship-to destination for the compounds (dollars in thousands):

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31,

 

December 31,

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

North America

 

  $

9,543

 

  $

7,408

 

  $

17,396

 

  $

13,114

Europe

 

86

 

271

 

109

 

309

Asia Pacific

 

15

 

10

 

29

 

13

 

 

  $

9,644

 

  $

7,689

 

  $

17,534

 

  $

13,436

 

Significant Collaborators

 

The following collaborators contributed greater than 10% of total revenue during the periods set forth below:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31,

 

December 31,

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

Genentech, Inc.

 

46.3%

 

60.5%

 

54.3%

 

63.9%

Celgene Corporation

 

42.5%

 

18.6%

 

32.7%

 

21.3%

VentiRx Pharmaceuticals, Inc.

 

0.1%

 

16.3%

 

0.6%

 

11.3%

 

 

88.9%

 

95.4%

 

87.6%

 

96.5%

 

The loss of one or more significant collaborators could have a material adverse effect on the Company’s business, operating results or financial condition. The Company does not require collateral to secure the payment obligations of its collaborators. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, most collaborators pay in advance and management does not believe significant credit risk exists as of December 31, 2009.

 

NOTE 3 - MARKETABLE SECURITIES

 

The Company’s investments in marketable securities include domestic public corporate debt securities, commercial paper issued by domestic public companies, obligations of U.S. federal government agencies and ARS. All of these investments are held in the name of the Company at a limited number of financial institutions. The Company’s investments in marketable securities were all classified as available-for-sale as of December 31, 2009 and June 30, 2009.

 

14



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Marketable securities consisted of the following as of December 31, 2009 (dollars in thousands):

 

 

 

 

 

 

Gross

 

Gross

 

 

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

Cost

 

Gains

 

Losses

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Government agency securities

 

$

-

 

 

$

-

 

 

$

-

 

 

$

-

 

Mutual fund securities

 

270

 

 

-

 

 

-

 

 

270

 

Sub-total

 

270

 

 

-

 

 

-

 

 

270

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

Auction rate securities

 

11,386

 

 

5,243

 

 

-

 

 

16,629

 

Mutual fund securities

 

703

 

 

-

 

 

 

 

 

703

 

Sub-total

 

12,089

 

 

5,243

 

 

-

 

 

17,332

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$

12,359

 

 

$

5,243

 

 

$

-

 

 

$

17,602

 

 

Marketable securities consisted of the following as of June 30, 2009 (dollars in thousands):

 

 

 

 

 

 

Gross

 

Gross

 

 

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

Cost

 

Gains

 

Losses

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Government agency securities

 

7,059

 

 

-

 

 

-

 

 

7,059

 

Mutual fund securities

 

237

 

 

-

 

 

-

 

 

237

 

Sub-total

 

7,296

 

 

-

 

 

-

 

 

7,296

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

Auction rate securities

 

13,284

 

 

3,234

 

 

-

 

 

16,518

 

Mutual fund securities

 

472

 

 

-

 

 

-

 

 

472

 

Sub-total

 

13,756

 

 

3,234

 

 

-

 

 

16,990

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$

21,052

 

 

$

3,234

 

 

$

-

 

 

$

24,286

 

 

The fair value measurement categories of these marketable securities as of December 31, 2009 and June 30, 2009 were as follows (dollars in thousands):

 

 

 

December 31,

 

June 30,

 

 

2009

 

2009

 

 

 

 

 

 

 

Quoted prices in active markets for identical assets (Level 1)

 

$

973

 

 

$

7,768

 

Significant unobservable inputs (Level 3)

 

16,629

 

 

16,518

 

 

 

$

17,602

 

 

$

24,286

 

 

15



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

The amortized cost and estimated fair value of available-for-sale securities by contractual maturity as of December 31, 2009 is as follows (dollars in thousands):

 

 

 

Amortized

 

Fair

 

 

Cost

 

Value

 

 

 

 

 

 

 

Due in one year or less

 

$

270

 

 

$

270

 

Due in one year to three years

 

703

 

 

703

 

Due after 10 years or more

 

11,386

 

 

16,629

 

 

 

$

12,359

 

 

$

17,602

 

 

Auction Rate Securities

 

During the fiscal year ended June 30, 2008, auctions for all of the ARS were unsuccessful.  During the first quarter of fiscal 2009, auctions for the ARS that the Company holds were suspended.  The lack of successful auctions resulted in the interest rate on these investments increasing to LIBOR plus additional basis points as stipulated in the auction rate agreements, ranging from 200 to 350 additional basis points, which has continued through the current fiscal quarter. While the Company now earns a higher contractual interest rate on these investments, the investments are not currently liquid and may not be liquid at a time when the Company needs to access these funds. In the event the Company needs to access these funds and liquidate the ARS prior to the time auctions of these investments are successful or the date on which the original issuers retire these securities, the Company may be required to sell them in a distressed sale in a secondary market, most likely for a lower value than their current fair value.

 

As of December 31, 2009, the Company held six securities with a par value of $28.9 million and a fair value of $16.6 million.  As of June 30, 2009, the Company held seven securities with a par value of $32.9 million and a fair value of $16.5 million.  The Company sold one of the ARS in the second quarter of fiscal 2010 with a par value of $4 million for $2.8 million and realized a gain of $1.2 million, of which $394 thousand was reclassified to earnings from Accumulated Other Comprehensive Income.

 

Under the fair value hierarchy, the Company’s ARS are measured using Level III, or unobservable inputs, as there is no active market for the securities.  The most significant unobservable inputs used in this method are estimates of the amount of time until a liquidity event will occur and the discount rate, which incorporates estimates of credit risk and a liquidity premium (discount). Due to the inherent complexity in valuing these securities, the Company engaged a third-party valuation firm to perform an independent valuation of the ARS beginning with the first quarter of fiscal 2009 and continuing through the current fiscal quarter.

 

While the Company believes that the estimates used in the fair value analysis are reasonable, a change in any of the assumptions underlying these estimates would result in different fair value estimates for the ARS and could result in additional changes to the ARS values, either increasing or decreasing their value.

 

16



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Based on its fair value analysis and fair value estimates as of each quarter end, the Company recorded adjustments to the fair value of its ARS that are summarized below (dollars in thousands):

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31,

 

December 31,

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gains

 

$

506

 

 

$

-

 

 

$

2,404

 

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gains attributable to the change in unrealized gains

 

$

394

 

 

$

-

 

 

$

394

 

 

$

-

 

Other current period gains

 

771

 

 

-

 

 

771

 

 

-

 

 

 

$

1,165

 

 

$

-

 

 

$

1,165

 

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Losses attributable to the change in unrealized losses

 

$

-

 

 

$

-

 

 

$

-

 

 

$

(1,939

)

Other current period losses

 

-

 

 

(10,452

)

 

(217

)

 

(12,423

)

 

 

$

-

 

 

$

(10,452

)

 

$

(217

)

 

$

(14,362

)

 

The Company has recorded cumulative net fair value declines of $12.3 million to the ARS for the six securities held as of December 31, 2009.

 

A rollforward of adjustments to the fair value of the ARS for the six months ended December 31, 2009 and 2008 follows (dollars in thousands):

 

 

 

Six Months Ended

 

 

December 31,

 

 

2009

 

2008

 

 

 

 

 

 

 

Balance as of prior year end

 

$

16,518

 

 

$

29,089

 

Add: Current period gains included in equity

 

2,404

 

 

-

 

Add: Current period gains included in earnings

 

771

 

 

-

 

Less: Cost basis of ARS sold

 

(2,847

)

 

-

 

Less: Current period losses included in earnings

 

(217

)

 

(12,423

)

Balance as of current quarter end

 

$

16,629

 

 

$

16,666

 

 

17



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

NOTE 4 – DEFERRED REVENUE

 

Deferred revenue consisted of the following (dollars in thousands):

 

 

 

December 31,

 

June 30,

 

 

2009

 

2009

 

 

 

 

 

 

 

Amgen, Inc.

 

$

59,097

 

 

$

-

 

Celgene Corporation

 

28,689

 

 

34,429

 

Genentech, Inc.

 

4,610

 

 

5,060

 

Other

 

-

 

 

84

 

Total deferred revenue

 

92,396

 

 

39,573

 

Less: Current portion

 

(40,634

)

 

(11,233

)

Deferred revenue, long term

 

$

51,762

 

 

$

28,340

 

 

Amgen Inc.

 

In December 2009, the Company granted Amgen the exclusive worldwide right to develop and commercialize the Company’s small-molecule glucokinase activator, AMG 151 / ARRY-403. Under the Collaboration and License Agreement, the Company is responsible for completing Phase 1 clinical trials on AMG 151 / ARRY-403. The Company will also conduct further research funded by Amgen to create second generation glucokinase activators. Amgen is responsible for further development and commercialization of AMG 151 / ARRY-403 and any resulting second generation compounds. The Agreement also provides the Company with an option to co-promote any approved drugs with Amgen in the U.S. with certain limitations.

 

In partial consideration for the rights granted to Amgen under the Agreement, Amgen paid the Company an up-front fee of $60 million. Amgen will also pay the Company for research on second generation compounds based on the number of full-time-equivalent scientists working on the discovery program. The Company is also entitled to receive up to approximately $666 million in aggregate milestone payments if all clinical and commercialization milestones specified in the Agreement for AMG 151 / ARRY-403 and at least one backup compound are achieved, as well as royalties on sales of any approved drugs developed under the Agreement.

 

The Company estimates that its obligations under the Agreement will continue until December 31, 2012 and, therefore, is recognizing the up-front fee from the date the Agreement was signed on December 13, 2009 through that time.  The Company recognized $903 thousand of revenue for the three months ended December 31, 2009, which is recorded in License and Milestone Revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

Either party may terminate the Agreement in the event of a material breach of a material obligation under the Agreement by the other party upon 90 days prior notice, and Amgen may terminate the Agreement at any time upon notice of 60 or 90 days depending on the development activities going on at the time of such notice.  The parties have also agreed to indemnify each other for certain liabilities arising under the Agreement.

 

Celgene Corporation

 

In September 2007, the Company entered into a worldwide strategic collaboration with Celgene focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation. Under the agreement, Celgene made an up-front payment of $40 million to the Company to provide

 

18



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

research funding for activities conducted by the Company under the agreement. The Company is responsible for all discovery and clinical development through Phase 1 or Phase 2a. Celgene has an option to select a limited number of drugs developed under the collaboration that are directed to up to two of four mutually selected discovery targets and will receive exclusive worldwide rights to the drugs, except for limited co-promotional rights in the U.S. Celgene’s option may be exercised with respect to drugs directed at any of the four targets at any time until the earlier of completion of Phase 1 or Phase 2a trials for the drug or September 2014. Additionally, the Company is entitled to receive, for each drug for which Celgene exercises an option, potential milestone payments of $200 million, if certain discovery, development and regulatory milestones are achieved and an additional $300 million if certain commercial milestones are achieved, as well as royalties on net sales. The Company retains all rights to the other programs. In June 2009, the parties amended the Celgene agreement to substitute a new discovery target in place of an existing target, and Celgene paid the Company $4.5 million in consideration for the amendment. No other provisions of the agreement with Celgene were modified by the amendment.  In September 2009, Celgene notified the Company it was waiving its rights to one of the programs, leaving them the option to select two of the remaining three targets.

 

The Company had previously estimated that its discovery obligations under the Agreement would continue through September 2014 and accordingly was recognizing as revenue the up front fees received from the date of receipt through September 2014.  Effective October 1, 2009, the Company estimates that its discovery efforts under the Agreement will conclude by September 2011 and the Company would complete its obligations at that time.  Therefore, the unamortized balance as of September 30, 2009 is being amortized over the revised shorter period.  The Company recognized $4.1 million and $1.4 million for the three months ended December 31, 2009 and 2008, respectively, which is recorded in License and Milestone Revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss.  The Company recognized $5.7 million and $2.9 million for the six months ended December 31, 2009 and 2008, respectively, which is recorded in License and Milestone Revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

Celgene can also choose to terminate any drug development program for which it has not exercised an option at any time, provided that it must give the Company prior notice. In this event, all rights to the program remain with the Company and it would no longer be entitled to receive milestone payments for further development or regulatory milestones that it could have achieved Celgene had continued development of the program. Celgene may terminate the agreement in whole, or in part with respect to individual drug development programs for which Celgene has exercised its option, upon six months’ written notice to the Company. In addition, either party may terminate the agreement, following certain cure periods, in the event of a breach by the other party of its obligations under the agreement.

 

NOTE 5 – LONG-TERM DEBT

 

Long-term debt consists of the following (dollars in thousands):

 

 

 

 

December 31,

 

June 30,

 

 

2009

 

2009

 

 

 

 

 

 

 

Credit facility

 

$

126,762

 

 

$

86,286

 

Term loan

 

10,000

 

 

10,000

 

Equipment line of credit

 

5,000

 

 

5,000

 

Long-term debt, gross

 

141,762

 

 

101,286

 

Less: Unamortized discount on credit facility

 

(32,061

)

 

(18,116

)

Long-term debt, net

 

109,701

 

 

83,170

 

Less: Current portion

 

(15,000

)

 

(15,000

)

Long-term debt

 

$

94,701

 

 

$

68,170

 

 

19



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Deerfield Credit Facilities

 

The Company has entered into two credit facilities (the “Credit Facilities”) with Deerfield Private Design Fund, L.P. and Deerfield Private Design International Fund, L.P. (collectively “Deerfield”), health care investment funds. Under a Facility Agreement entered into with Deerfield in April 2008, the Company borrowed a total of $80 million (the “2008 Loan”), which was funded in two $40 million payments in June 2008 and December 2008. Certain terms of the 2008 Credit Facility, including the interest rate and payment terms applicable to the 2008 Loan and covenants relating to minimum cash and cash equivalent balances the Company must maintain, were amended in May 2009 when the Company entered into a new Facility Agreement with Deerfield, under which the Company borrowed $40 million (the “2009 Loan”), which it drew down on July 31, 2009.

 

The outstanding principal and interest on the Credit Facilities is due on or before April 2014 and, at the Company’s option, may be repaid at any time with shares of the Company’s common stock that have been registered under the Securities Act of 1933, as amended, with certain restrictions, or in cash. The maximum number of shares that the Company can issue to Deerfield under the Credit Facilities is 9,622,220 shares, without obtaining stockholder approval.

 

The Company made quarterly interest payments under the 2008 Loan during fiscal 2009 and the first quarter of fiscal 2010 that accrued on the total $80 million principal balance. Interest accrued at a 2.0% annual rate from the date of the Facility Agreement for the 2008 Loan through the July 31, 2009 disbursement of the 2009 Loan. In addition, compound interest accrued quarterly during this same period at an additional 6.5% annual rate on the total $80 million principal loan balance, which was added to the amounts already accrued.

 

Simple interest began to accrue on the 2009 Loan when it was drawn on July 31, 2009 at the rate of 7.5% per annum. This rate will continue to apply as long as the Company’s total Cash and Cash Equivalents and Marketable Securities on the first business day of each month during which such principal amounts remain outstanding is at least $60 million. If the Company’s total Cash and Cash Equivalents and Marketable Securities in any month are less than $60 million, the interest rate is adjusted to a rate between 8.5% per annum and 14.5% per annum for every $10 million by which it is less than $60 million as follows:

 

Total Cash, Cash Equivalents and Marketable Securities

 

Applied Interest
Rate

 

 

 

$60 million or greater

 

7.50%

Between $50 million and $60 million

 

8.50%

Between $40 million and $50 million

 

9.50%

Between $30 million and $40 million

 

12.00%

Less than $30 million

 

14.50%

 

The 2009 Credit Facility amended the interest rate provisions of the 2008 Credit Facility.  Effective as of July 31, 2009, interest began accruing on the $80 million principal amount of the 2008 Loan, exclusive of interest that had been added to the principal amount, at the rates applicable to the 2009 Loan described above, and no additional compound interest will apply. In addition, as of the July 31, 2009 disbursement date of the 2009 Loan, interest became payable monthly on both Credit Facilities.

 

The variable interest rate structure under the Credit Facilities is considered an embedded derivative.    Deerfield also has limited rights to accelerate the loan upon certain changes of control of the Company or an event of default. This change of control provision is considered a significant transaction contingent put

 

20



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

option and is also an embedded derivative.   As discussed in Note 1 “Overview and Basis of Presentation – Long-term Debt and Embedded Derivatives,” these derivatives must be valued and reported separately in the Company’s financial statements, and are collectively referred to as the “Embedded Derivatives.”

 

Under the fair value hierarchy, the Company measured the fair value of the Embedded Derivatives using Level III, or unobservable inputs.  To estimate fair value of the Embedded Derivatives, the Company made assumptions as to interest rate behaviors and the impact of repaying the debt at maturity in cash and/or stock. To estimate the fair value of the variable interest rate feature as of July 31, 2009, which is tied to the Company’s cash and cash equivalent balances during the term of the Credit Facilities, the Company projected its cash balances over this period, including forecasts of up-front revenue from new collaboration arrangements, milestone payments, other revenue, funds to be provided from issuances of debt and/or equity, costs and expenses and other items. Such forecasts are inherently subjective and, although management believes the assumptions upon which they are based are reasonable, may not reflect actual results. Based on this analysis, the Company estimated the effective interest rate to be 7.55% as of July 31, 2009.

 

To estimate the fair value of the put right, the Company estimated the probability of a change in control that would trigger Deerfield’s acceleration rights as specified in the loan provisions.  The Company’s evaluation of this probability was based on its expectations as to the size and financial strength of probable acquirers, including history of collaboration partners, the probability of an acquisition occurring during the term of the Credit Facilities and other factors, all of which are inherently uncertain and difficult to predict.  The Company estimated the probability of Deerfield exercising the change in control put to be 5% at July 31, 2009.

 

Based on these assumptions, the Embedded Derivatives were initially valued as of July 31, 2009 at $1.1 million and recorded as Derivative Liabilities and as Debt Discount in the accompanying Condensed Balance Sheets.  As of September 30, 2009 and December 31, 2009, the Company re-valued the effective interest rate and the probability of the exercise of the change in control put.  The assumptions used at July 31, 2009, described above, did not change at September 30, 2009, and the estimated fair value of the Embedded Derivatives was determined to be $938 thousand.  The assumptions used at December 31, 2009 for the effective interest rate changed nominally to 7.54%.  The assumption for the probability of the exercise of the change of control put as of December 31, 2009 remained the same.  The estimated fair value of the Embedded Derivatives was determined to be $857 thousand as of December 31, 2009.

 

The change in value of the Embedded Derivatives of $81 thousand and $206 thousand was recorded as a reduction to Interest Expense in the accompanying Statements of Operations and Comprehensive Loss for the three and six months ended December 31, 2009, respectively.  Management will re-assess these assumptions at each reporting date, and future changes to these assumptions could materially change the estimated fair value of the Embedded Derivatives, with a corresponding impact on the Company’s reported results of operations.

 

The Company estimated that the fair value of the Deerfield debt was $89.6 million and $48.7 million at December 31, 2009 and June 30, 2009, respectively. The primary reason for the difference in fair value is that the Company had drawn only $80 million of the total $120 million under the Credit Facilities as of June 30, 2009.

 

The Company paid Deerfield transaction fees totaling $2 million when the Company drew the funds under the 2008 Loan, and $500 thousand on July 10, 2009 and $500 thousand when the funds were drawn on July 31, 2009 under the 2009 Credit Facility. The transaction fees are included in Other Long-term Assets in the accompanying Condensed Balance Sheets. The Company is amortizing these transaction fees to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss over the respective terms of each of the Credit Facilities. Other direct issuance costs in connection with the transactions were expensed as incurred and were not significant.

 

21



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

The Credit Facilities are secured by a second priority security interest in the Company’s assets, including accounts receivable, equipment, inventory, investment property and general intangible assets, excluding copyrights, patents, trademarks, service marks and certain related intangible assets. This security interest and the Company’s obligations under the Credit Facilities are subordinate to the Company’s obligations to Comerica Bank, and to Comerica’s security interest, under the Loan and Security Agreement between the Company and Comerica Bank dated June 28, 2005, as amended, discussed below.

 

The Facility Agreements for both Credit Facilities contain representations, warranties and affirmative and negative covenants that are customary for credit facilities of this type. The Facility Agreements restrict the Company’s ability to, among other things, sell certain assets, engage in a merger or change in control transaction, incur debt, pay cash dividends and make investments. The Facility Agreements also contain events of default that are customary for credit facilities of this type, including payment defaults, covenant defaults, insolvency type defaults and events of default relating to liens, judgments, material misrepresentations and the occurrence of certain material adverse events. In addition, if the Company’s total Cash, Cash Equivalents and Marketable Securities at the end of a fiscal quarter fall below $20 million (which was reduced from $40 million when the Company entered into the 2009 Credit Facility), all amounts outstanding under the Credit Facilities become immediately due and payable. The Company is also required, subject to certain exceptions and conditions, to make payments of principal equal to 15.0% of certain amounts it receives under collaboration, licensing, partnering, joint venture and other similar arrangements entered into after January 1, 2011.

 

Warrants Issued to Deerfield

 

In consideration for providing the 2008 Credit Facility, the Company issued warrants to Deerfield to purchase 6,000,000 shares of common stock at a price of $7.54 per share (the “Prior Warrants”). In May 2009, these warrants were exchanged for new warrants (“Exchange Warrants”) to purchase 6,000,000 shares of common stock at an exercise price of $3.65 per share in connection with the execution of the Facility Agreement for the 2009 Loan, as described below.

 

Pursuant to the terms of the Facility Agreement for the 2009 Loan, the Company issued Deerfield warrants to purchase an aggregate of 6,000,000 shares of the Company’s Common Stock (the “New Warrants” and collectively with the Exchange Warrants, the “Warrants”) when the funds were disbursed on July 31, 2009.

 

The Exchange Warrants contain substantially the same terms as the Prior Warrants, except that the Exchange Warrants are not exercisable until six months from the July 31, 2009 disbursement date and have a per share exercise price equal to $3.65, which was reduced from the $7.54 exercise price of the Prior Warrants. The New Warrants have a per share exercise price equal to $4.19. The Warrants are exercisable commencing six months after the July 31, 2009 issuance date and expire on April 29, 2014. All other provisions of the Exchange Warrants and the New Warrants are identical.

 

The Company allocated the $80 million proceeds under the 2008 Loan between the debt and the Prior Warrants based upon their estimated relative fair values.  The Company valued the Prior Warrants using the Black-Scholes option pricing model using the following assumptions:

 

·                  Risk-free interest rate of 3.3%;

·                  Volatility of 63.9%;

·                  Expected life of six years; and

·                  Dividend yield of zero.

 

The Company allocated $20.6 million in value to equity and recorded it as Debt Discount in the accompanying Condensed Balance Sheets.  Because the 2008 Loan was drawn down in two separate tranches, the Company is amortizing half of the Prior Warrant value from the first draw date and the

 

22



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

remaining half from the second draw date, in both cases to the end of the credit facility term, to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

The Company allocated the $40 million proceeds under the 2009 Loan between the debt and the New Warrants based upon their estimated relative fair values.  The Company valued the New Warrants using the Black-Scholes option pricing model using the following assumptions:

 

·                  Risk-free interest rate of 2.46%;

·                  Volatility of 63.59%;

·                  Expected life of five years; and

·                  Dividend yield of zero.

 

The Company allocated $12.4 million in value to equity and recorded it as Debt Discount.  The Company is amortizing the discount from the July 31, 2009 draw date to the end of the Credit Facility term to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

The Company calculated the incremental value of the Exchange Warrants as the difference between the value of the Exchange Warrants at the new exercise price ($3.65) and the value of the Prior Warrants at the prior exercise price ($7.54). The Black-Scholes option pricing models used to calculate these values used the following assumptions:

 

·                  Risk-free interest rate of 1.86%;

·                  Volatility of 61.94%;

·                  Expected life of five years; and

·                  Dividend yield of zero.

 

Prior to disbursement of the 2009 Loan, the Company recorded the incremental value of the Exchange Warrants of $3.3 million as of June 30, 2009 in Other Long-Term Assets and Warrants in the accompanying Condensed Balance Sheets.  Following disbursement of the 2009 Loan on July 31, 2009, the Company reclassified, the balance in Other Long-Term Assets to Debt Discount and began amortizing the discount to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss from July 31, 2009 to the end of the term of the Credit Facilities.

 

A reconciliation of the total interest expense recognized by the Company for the Deerfield Credit Facilities for the three and six months ended December 31, 2009 and 2008 follows (dollars in thousands).

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31,

 

December 31,

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

 

2.0% simple interest

 

$

-

 

 

$

403

 

 

$

124

 

 

$

807

 

6.5% compounding interest

 

-

 

 

1,347

 

 

476

 

 

2,672

 

7.5% simple interest

 

2,250

 

 

-

 

 

3,750

 

 

-

 

Amortization of the transaction fees

 

143

 

 

48

 

 

268

 

 

91

 

Amortization of the debt discounts

 

1,540

 

 

434

 

 

2,824

 

 

817

 

Change in value of the Embedded Derivatives

 

(81

)

 

-

 

 

(206

)

 

-

 

Total interest expense on the Deerfield Credit Facility

 

$

3,852

 

 

$

2,232

 

 

$

7,236

 

 

$

4,387

 

 

Term Loan and Equipment Line of Credit

 

The Company entered into a Loan and Security Agreement (“Loan and Security Agreement”) with Comerica Bank dated June 28, 2005, which was has been subsequently amended. The Loan and

 

23



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Security Agreement provides for a term loan, equipment advances and a revolving line of credit, all of which are secured by a first priority security interest in the Company’s assets, other than its intellectual property.

 

The full $10 million term loan was advanced to the Company on June 30, 2005.   The Company received the total $5 million of equipment advances by June 30, 2007.

 

Total available revolving lines of credit of $6.8 million have been issued to support outstanding standby letters of credit in relation to the Company’s facilities leases. These standby letters of credit expire on January 31, 2014 and August 31, 2016.

 

Should the Company maintain less than $10 million at Comerica Bank at any time during any interest rate period, the interest rate the Company pays will be 0.50% higher than the then applicable rate. Interest is payable monthly on the outstanding borrowings.

 

On September 30, 2009, the term and the interest rate structure of the Loan and Security Agreement were amended.  The maturity date was extended 120 days from June 28, 2010 to October 26, 2010.  Effective October 1, 2009, the outstanding balances under the term loan and the equipment advances will bear interest on a monthly basis at a rate equal to 2.75% above the Prime Rate, as quoted by Comerica Bank, but not less than the sum of Comerica Bank’s daily adjusting LIBOR rate plus 2.5% per annum.

 

As of December 31, 2009, both the term loan and the equipment advances had an interest rate of 6.0% per annum. As of December 31, 2008, the term loan and the equipment advances had an interest rate of 1.5%. The Company recognized $239 thousand and $77 thousand of interest for the three months ended December 31, 2009 and 2008, respectively. The Company recognized $297 thousand and $201 thousand of interest for the six months ended December 31, 2009 and 2008, respectively. These charges are recorded in Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

The following table outlines the level of Cash, Cash Equivalents and Marketable Securities the Company must hold in accounts at Comerica Bank per the Loan and Security Agreement based on the Company’s total Cash, Cash Equivalent and Marketable Securities.

 

Total Cash, Cash Equivalents and Marketable Securities

 

Cash on Hand
at Comerica

 

 

 

 

Greater than $40 million

 

$

-

 

Between $30 million and $40 million

 

$

2,000,000

 

Between $27.5 million and $30 million

 

$

13,000,000

 

Less than $27.5 million

 

$

24,000,000

 

 

In addition, if the Company’s total Cash, Cash Equivalents and Marketable Securities, including amounts invested at Comerica Bank, falls below $24 million, the loans become immediately due and payable.

 

The Loan and Security Agreement contains representations and warranties and affirmative and negative covenants that are customary for credit facilities of this type. The Loan and Security Agreement restricts the Company’s ability to, among other things, sell certain assets, engage in a merger or change in control transaction, incur debt, pay cash dividends and make investments. The Loan and Security Agreement also contains events of default that are customary for credit facilities of this type, including payment

 

24



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

defaults, covenant defaults, insolvency type defaults and events of default relating to liens, judgments, material misrepresentations and the occurrence of certain material adverse events.

 

The estimated fair value of the Loan and Security Agreement was $15 million and $14.3 million as of December 31, 2009 and June 30, 2009, respectively.

 

Commitment Schedule

 

A summary of the Company’s contractual commitments as of December 31, 2009 under the Credit Facilities and the Loan and Security Agreement discussed above are as follows (dollars in thousands):

 

For the twelve months ended December 31,

 

 

 

2010

 

$

15,000

 

2011

 

-

 

2012

 

-

 

2013

 

-

 

2014

 

126,762

 

 

 

$

141,762

 

 

NOTE 6 – NET LOSS PER SHARE

 

As a result of the Company’s net losses for the three-month periods ended December 31, 2009 and 2008 all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share. As of December 31, 2009 and 2008, the number of potentially dilutive common stock equivalents excluded from the diluted net loss per share calculations was 385,085 shares and 1,058,322 shares, respectively.

 

NOTE 7 – SHARE BASED COMPENSATION EXPENSE

 

The Company adopted the modified prospective method for expensing share-based compensation as of July 1, 2005, which requires that all share-based payments to employees be recognized in the Condensed Statements of Operations and Comprehensive Loss at the fair value of the award on the grant date.  Under this method, the Company recognizes compensation expense equal to the grant date fair value for all share-based payments (i) granted prior to, but not yet vested, as of July 1, 2005 and (ii) granted on or after July 1, 2005.  Shared-based compensation arrangements include stock option grants under the Option Plan and purchases of common stock at a discount under the ESPP.  The fair values of all stock options granted by the Company are estimated on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term of stock option grants.  See Note 13 “Employee Compensation Plans” to the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended June 30, 2009 for more information about the assumptions used by the Company under this valuation methodology.   During the three and six months ended December 31, 2009, the Company made no material changes to these assumptions.

 

During the three months ended December 31, 2009 and 2008, the Company issued new stock options to purchase a total of 214 thousand shares and 137 thousand shares of common stock, respectively.  The Company recognized compensation expense related to stock options of $1.2 million and $1.3 million for the three months ended December 31, 2009 and 2008, respectively.

 

During the six months ended December 31, 2009 and 2008, the Company issued new stock options to purchase a total of 255 thousand shares and 1.3 million shares of common stock, respectively.  The

 

25



Table of Contents

 

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the quarter ended December 31, 2009

(Unaudited)

 

Company recognized compensation expense related to stock options of $2.5 million and $2.4 million for the six months ended December 31, 2009 and 2008, respectively.

 

As of December 31, 2009, there was $5.7 million of total unrecognized compensation expense, including the impact of expected forfeitures, related to unvested share-based compensation awards granted under the Company’s equity plans, which the Company expects to recognize over a weighted-average period of 2.2 years.

 

The fair value of common stock purchased under the ESPP is based on the estimated fair value of the common stock during the offering period and the percentage of the purchase discount.  During the three months ended December 31, 2009 and 2008, the Company recognized compensation expense related to its ESPP of $246 thousand and $142 thousand, respectively.  During the six months ended December 31, 2009 and 2008, the Company recognized compensation expense related to its ESPP of $430 thousand and $273 thousand, respectively.

 

NOTE 8 – EQUITY DISTRIBUTION AGREEMENT

 

On September 18, 2009, the Company entered into an Equity Distribution Agreement with Piper Jaffray & Co. (the “Agent”) pursuant to which the Company agreed to sell from time to time, up to an aggregate of $25 million in shares of its $.001 par value common stock, through the Agent that have been registered on a registration statement on Form S-3 (File No. 333-15801). Sales of the shares made pursuant to the Equity Distribution Agreement, if any, will be made on the NASDAQ Stock Market by means of ordinary brokers’ transactions at market prices. Additionally, under the terms of the Equity Distribution Agreement, the Company may sell shares of its common stock through the Agent, on the NASDAQ Global Market or otherwise, at negotiated prices or at prices related to the prevailing market price.

 

During the three months ended December 31, 2009, the Company sold 696,700 shares of common stock at an average price of $2.81 per share, and received gross proceeds of $2 million.  The Company paid commissions to the Agent relating to these sales equal to $59 thousand and other expenses relating to the closing of the Equity Distribution Agreement totaling $2 thousand.

 

During the six months ended December 31, 2009, the Company sold 756,690 shares of common stock at an average price of $2.80 per share, and received gross proceeds of $2.1 million.  The Company paid commissions to the Agent relating to these sales equal to $64 thousand and other expenses relating to the closing of the Equity Distribution Agreement totaling $242 thousand.

 

NOTE 9 – EMPLOYEE BONUS

 

On October 5, 2009, the Company paid bonuses to approximately 350 eligible employees having an aggregate value of $3.9 million under the fiscal 2009 Performance Bonus Program through the issuance of a total of 1,000,691 shares of its common stock valued at $2.4 million and payment of cash to satisfy related withholding taxes.  The liability for the bonus as of June 30, 2009 is recorded in Accrued Compensation and Benefits in the accompanying Condensed Balance Sheets.

 

26



Table of Contents

 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our expectations related to the progress and success of drug discovery activities conducted by Array and by our collaborators, our ability to obtain additional capital to fund our operations and/or reduce our research and development spending, realizing new revenue streams and obtaining future out-licensing collaboration agreements that include up-front milestone and/or royalty payments, our ability to realize up-front milestone and royalty payments under our existing or any future agreements, future research and development spending and projections relating to the level of cash we expect to use in operations, our working capital requirements and our future headcount requirements. In some cases, forward-looking statements can be identified by the use of terms such as “may,” “will,” “expects,” “intends,” “plans,” “anticipates,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terms. These statements are based on current expectations, projections and assumptions made by management and are not guarantees of future performance. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, these expectations or any of the forward-looking statements could prove to be incorrect, and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties, including but not limited to the factors set forth under the heading “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009.  All forward looking statements are made as of the date hereof, and, unless required by law, we undertake no obligation to update any forward-looking statements.

 

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes to those statements included elsewhere in this quarterly report. The terms “we,” “us,” “our” and similar terms refer to Array BioPharma Inc.

 

Overview

 

We are a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins. In addition, leading pharmaceutical and biotechnology companies partner with us to discover and develop drug candidates across a broad range of therapeutic areas.

 

The five most advanced wholly-owned programs in our development pipeline are as follows:

 

1.             ARRY-162, a MEK inhibitor for cancer

2.             ARRY-380, a HER2 inhibitor for breast cancer

3.             ARRY-520, a KSP inhibitor for acute myeloid leukemia, or AML, and multiple myeloma, or MM

4.             ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome, or MDS

5.             ARRY-543, a HER2/EGFR inhibitor for solid tumors

 

In addition to these proprietary development programs, we have seven partnered drugs in clinical development:

 

1.             AMG 151 / ARRY-403, a glucokinase activator for Type 2 diabetes, partnered with Amgen Inc.

2.             AZD6244, a MEK inhibitor for cancer, partnered with AstraZeneca, PLC

3.             AZD8330, a MEK inhibitor for cancer, partnered with AstraZeneca, PLC

4.             RG7227/ITMN-191, an NS3/4 protease inhibitor for Hepatitis C Virus, partnered with InterMune, Inc./Roche Holding AG

 

27



Table of Contents

 

5.             LY2603618/IC83, a Chk inhibitor for cancer, partnered with Eli Lilly and Company

6.             VTX-2337, a Toll-like receptor for cancer, partnered with VentiRx Pharmaceuticals, Inc.

7.             VTX-1463, a Toll-like receptor for allergy, partnered with VentiRx Pharmaceuticals, Inc.

 

We also have a portfolio of proprietary and partnered drug discovery programs that we believe will generate one to two Investigational New Drug, or IND, applications in fiscal 2010. Our discovery efforts have also generated additional early-stage drug candidates and we may choose to out-license select promising candidates through research partnerships prior to filing an IND application.

 

We have built our proprietary pipeline of research and development programs on spending of $385.5 million from our inception through December 31, 2009. Although we continue to commit significant resources to create our own proprietary drug candidates and to build a commercial-stage biopharmaceutical company, due to ongoing uncertainty in the capital markets as well as general economic conditions that have negatively affected the biopharmaceutical market, we reduced our spending on our proprietary discovery and development programs to focus on advancing our most promising clinical programs through proof-of-concept, which we believe will maximize their value, and, on our most promising discovery candidates. In the second quarter of fiscal 2010 and 2009, our spending on research and development for proprietary drug discovery was $19.1 million and $23.7 million, respectively.  In the first half of fiscal 2010 and 2009, our spending on research and development for proprietary drug discovery was $38.3 million and $48.2 million, respectively.   In fiscal 2009, we spent $89.6 million in research and development for proprietary drug discovery expenses, as compared to $90.3 million and $57.5 million for fiscal years 2008 and 2007, respectively.

 

As part of efforts to conserve our capital resources, we reduced our workforce in January 2009 by approximately 40 employees, or 10%, who were primarily in discovery research and support positions, resulting in a restructuring charge of approximately $1.5 million in the third quarter of fiscal 2009. We are also accelerating our efforts to partner select discovery and development programs that will provide funding, development and commercial resources, with the goal of optimizing the value of our drug portfolio. Our current quarterly cash used in operations is approximately $21 million per quarter.

 

We have received a total of $417.3 million in research funding and in up-front and milestone payments from our collaboration partners through December 31, 2009. Under our existing collaboration agreements, we have the potential to earn over $2.0 billion in additional milestone payments if we or our collaborators achieve all the drug discovery objectives detailed in those agreements, as well as the potential to earn royalties on any resulting product sales from 16 drug development programs.

 

Our significant existing collaborators include:

 

·                Amgen Inc., which entered into a worldwide strategic collaboration with us to develop our glucokinase activator, AMG 151 / ARRY-403.

·                Genentech, Inc., which entered into a worldwide strategic collaboration agreement with us focused on the discovery, development and commercialization of novel therapeutics.

·                Celgene Corporation, which entered into a worldwide strategic collaboration agreement with us focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation.

·                  AstraZeneca, which licensed three of our MEK inhibitors for cancer, including AZD6244 (ARRY-886), which is currently in multiple Phase 2 clinical trials.

·                InterMune, Inc., which collaborated with us on the discovery of  RG7227/ITMN-191, a novel small molecule inhibitor of the Hepatitis C Virus NS3/4 protease.  InterMune and its development partner, Roche, have reported that they are currently advancing the drug in a Phase 2b trial evaluating ITMN-191 in combination with standard of care therapies.

 

Our fiscal year ends on June 30. When we refer to a fiscal year or quarter, we are referring to the year in which the fiscal year ends and the quarters during that fiscal year. Therefore, fiscal 2010 refers to the

 

28



Table of Contents

 

fiscal year ended June 30, 2010 and the second quarter of fiscal 2010 refers to the three months ended December 31, 2009.

 

Business Development and Collaborator Concentrations

 

We currently license or partner certain of our compounds and/or programs and enter into collaborations directly with pharmaceutical and biotechnology companies through opportunities identified by our business development group, senior management, scientists and customer referrals. In addition, we may license our compounds and enter into collaborations in Japan through an agent.

 

The following collaborators contributed greater than 10% of total revenue for the three and six months ended December 31, 2009 and 2008:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31,

 

December 31,

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

 

Genentech, Inc.

 

46.3

%

 

60.5

%

 

54.3

%

 

63.9

%

Celgene Corporation

 

42.5

%

 

18.6

%

 

32.7

%

 

21.3

%

VentiRx Pharmaceuticals, Inc.

 

0.1

%

 

16.3

%

 

0.6

%

 

11.3

%

 

 

88.9

%

 

95.4

%

 

87.6

%

 

96.5

%

 

In general, certain of our collaborators may terminate their collaboration agreements with 90 to 180 days’ prior notice. Our agreement with Genentech can be terminated with 120 days’ notice. Celgene may terminate its agreement with us with six months’ notice.   Amgen may terminate its agreement with us at any time upon notice of 60 or 90 days depending on the development activities going on at the time of such notice.

 

The following table details revenue from our collaborators by region based on the country in which collaborators are located or the ship-to destination for compounds (dollars in thousands):

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31,

 

December 31,

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

 

North America

 

$

9,543

 

 

$

7,408

 

 

$

17,396

 

 

$

13,114

 

Europe

 

86

 

 

271

 

 

109

 

 

309

 

Asia Pacific

 

15

 

 

10

 

 

29

 

 

13

 

 

 

$

9,644

 

 

$

7,689

 

 

$

17,534

 

 

$

13,436

 

 

All of our collaboration agreements are denominated in U.S. dollars.

 

29



Table of Contents

 

Critical Accounting Policies and Estimates

 

Management’s discussion and analysis of financial condition and results of operations are based upon our accompanying Condensed Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.  The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses as well as the disclosure of contingent assets and liabilities. We regularly review our estimates and assumptions. These estimates and assumptions, which are based upon historical experience and on various other factors believed to be reasonable under the circumstances, form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Reported amounts and disclosures may have been different had management used different estimates and assumptions or if different conditions had occurred in the periods presented.

 

Below is a discussion of the policies and estimates that we believe involve a high degree of judgment and complexity.

 

Fair Value Measurements

 

Our financial instruments are recognized and measured at fair value in our financial statements and mainly consist of cash and cash equivalents, marketable securities, long-term investments, trade receivables and payables, accrued outsourcing costs, accrued expenses, long-term debt, embedded derivatives associated with the long-term debt, and warrants. We use different valuation techniques to measure the fair value of assets and liabilities, as discussed in more detail below. Fair value is defined as the price that would be received to sell the financial instruments in an orderly transaction between market participants at the measurement date. We use a framework for measuring fair value based on a hierarchy that distinguishes sources of available information used in fair value measurements and categorizes them into three levels:

 

·

Level I:

Quoted prices in active markets for identical assets and liabilities.

·

Level II:

Observable inputs other than quoted prices in active markets for identical assets and liabilities.

·

Level III:

Unobservable inputs.

 

We disclose assets and liabilities measured at fair value based on their level in the hierarchy. Considerable judgment is required in interpreting market data to develop estimates of fair value for assets or liabilities for which there are no quoted prices in active markets, including auction rate securities, or ARS we hold, warrants issued by us or embedded derivatives associated with our long-term debt.  The use of different assumptions and/or estimation methodologies may have a material effect on their estimated fair value. Accordingly, the fair value estimates disclosed by us may not be indicative of the amount that we or holders of the instruments could realize in a current market exchange.

 

We periodically review the realizability of each investment when impairment indicators exist with respect to the investment. If an other-than-temporary impairment of the value of an investment is deemed to exist, the carrying value of the investment is written down to its estimated fair value.

 

Long-term Debt and Embedded Derivatives

 

The terms of our long-term debt are discussed in detail in Note 5 “Long-term Debt.” The accounting for these arrangements is complex and is based upon significant estimates by management. We review all debt agreements to determine the appropriate accounting treatment when the agreement is entered into, and review all amendments to determine if the changes require accounting for the amendment as a modification, or extinguishment and new debt.  We also review each long-term debt arrangement to determine if any feature of the debt requires bifurcation and/or separate valuation. These features include

 

30



Table of Contents

 

hybrid instruments, which are comprised of at least two components ((1) a debt host instrument and (2) one or more conversion features), warrants and other embedded derivatives, such as other rights of the debt holder.

 

We currently have two embedded derivatives related to our long-term debt with Deerfield Private Design Fund, L.P. and Deerfield Private Design International Fund, L.P. (who we refer to collectively as Deerfield).  The first is a variable interest rate structure that constitutes a liquidity-linked variable spread feature.  The second derivative is a significant transaction contingent put option relating to the ability of Deerfield to accelerate repayment of the debt in the event of certain changes in control of our company.  Collectively, they are referred to as the “Embedded Derivatives.”  Under the fair value hierarchy, our Embedded Derivatives are measured using Level III, or unobservable inputs, as there is no active market for them. The fair value of the variable interest rate structure is based on our estimate of the probable effective interest rate over the term of the Deerfield credit facilities. The fair value of the put option is based on our estimate of the probability that a change in control that triggers Deerfield’s right to accelerate the debt will occur.  With those inputs, the fair value of each Embedded Derivative is calculated as the difference between the fair value of the Deerfield credit facilities if the Embedded Derivatives are included, and the fair value of the Deerfield credit facilities if the Embedded Derivatives are excluded.  Due to the inherent complexity in valuing the Deerfield credit facilities and the Embedded Derivatives, we engaged a third-party valuation firm to perform the valuation as of July 31, 2009, the date funds were disbursed under the credit facility entered into in May 2009, and as of September 30, 2009 and December 31, 2009.  The estimated fair value of the Embedded Derivatives was determined based on management’s judgment and assumptions, and the use of different assumptions could result in significantly different estimated fair values.

 

The fair value of the Embedded Derivatives was initially recorded as Derivative Liabilities and as Debt Discount in our Condensed Balance Sheets. Any change in the value of the Embedded Derivatives is adjusted quarterly as appropriate and recorded to Derivative Liabilities in the Condensed Balance Sheets and Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.  The Debt Discount is being amortized from the draw date of July 31, 2009 to the end of the term of the Deerfield credit facilities using the effective interest method and recorded as Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

 

Warrants we issue in connection with our long-term debt arrangements are reviewed to determine if they should be classified as liabilities or as equity.  All outstanding warrants issued by us have been classified as equity.  We value the warrants at issuance based on a Black-Scholes option pricing model and then allocate a portion of the proceeds under the debt to the warrants based upon their relative fair values.

 

Any transaction fees paid in connection with our long-term debt arrangements are recorded as Other Long-Term Assets in the Condensed Balance Sheets and amortized to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss using the effective interest method over the term of the underlying debt agreement.

 

Marketable Securities

 

We have designated our marketable securities as of December 31, 2009 and June 30, 2009 as available-for-sale securities and account for them at their respective fair values. Marketable securities are classified as short-term or long-term based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying Condensed Balance Sheets. Marketable securities that are not considered available for use in current operations are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying Condensed Balance Sheets.

 

31



Table of Contents

 

Securities that are classified as available-for-sale are carried at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of Stockholders’ Deficit until their disposition. We review all available-for-sale securities each period to determine if it is more likely than not that they will remain available-for-sale based on our intent and ability to sell the security if we are required to do so. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in Interest Income in the accompanying Condensed Statements of Operations and Comprehensive Loss. Realized gains and losses are reported in Interest Income and Interest Expense, respectively, in the accompanying Condensed Statements of Operations and Comprehensive Loss as incurred. Declines in value judged to be other-than-temporary are reported in Impairment of Marketable Securities in the accompanying Condensed Statements of Operations and Comprehensive Loss as recognized. The cost of securities sold is based on the specific identification method.

 

Under the fair value hierarchy, our ARS are measured using Level III, or unobservable inputs, as there is no active market for the securities. The most significant unobservable inputs used in this method are estimates of the amount of time until a liquidity event will occur and the discount rate, which incorporates estimates of credit risk and a liquidity premium (discount). Due to the inherent complexity in valuing these securities, we engaged a third-party valuation firm to perform an independent valuation of the ARS beginning with the first quarter of fiscal 2009 and continuing through the current fiscal quarter. While we believe that the estimates used in the fair value analysis are reasonable, a change in any of the assumptions underlying these estimates would result in different fair value estimates for the ARS and could result in additional adjustments to the ARS, either increasing or further decreasing their value, possibly by material amounts.

 

See Note 3 “Marketable Securities” for additional information about our investments in ARS as well as “Other Income (Expense)” in the Results of Operations discussion in Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Quarterly Report on Form 10-Q.

 

Accrued Outsourcing Costs

 

Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations, and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate based on information we receive concerning changing circumstances, conditions or events that may affect such estimates.

 

Revenue Recognition

 

Most of our revenue is from research funding, up-front or license fees and milestone payments derived from discovering and developing drug candidates for our collaborators. Our agreements with collaboration partners include fees based on contracted annual rates for full-time-equivalent employees working on a program, and may also include non-refundable license and up-front fees, non-refundable milestone payments that are triggered upon achievement of specific research or development goals, and future royalties on sales of products that result from the collaboration. A small portion of our revenue comes from the sale of compounds on a per-compound basis. We report revenue for discovery, the sale of chemical compounds and the co-development of proprietary drug candidates we out-license, as

 

32



Table of Contents

 

Collaboration Revenue. License and Milestone Revenue is combined and consists of the current period’s recognized up-front fees and ongoing milestone payments from collaborators.

 

We recognize revenue in accordance with Staff Accounting Bulletin No. 104, Revenue Recognition (“SAB 104”). SAB 104 establishes four criteria, each of which must be met, in order to recognize revenue related to the performance of services or the shipment of products. Revenue is recognized when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable, and (d) collectability is reasonably assured.

 

Collaboration agreements that include a combination of discovery research funding, up-front or license fees, milestone payments and/or royalties are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet the separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting in accordance with SAB 104.

 

We recognize revenue from non-refundable up-front payments and license fees on a straight-line basis over the term of performance under the agreement, which is generally the estimated research term. These advance payments are deferred and recorded as Deferred Revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying Condensed Balance Sheets. When the performance period is not specifically identifiable from the agreement, we estimate the performance period based upon provisions contained within the agreement, such as the duration of the research term, the specific number of full-time-equivalent scientists working a defined number of hours per year at a stated price under the agreement, the existence, or likelihood of achievement, of development commitments, and other significant commitments of ours.

 

We also have agreements that provide for milestone payments.  In certain cases, a portion of each milestone payment is recognized as revenue when the specific milestone is achieved based on the applicable percentage of the estimated research or development term that has elapsed to the total estimated research and/or development term.  In other cases, when the milestone payment finances the future development obligations of the Company, the revenue is recognized on a straight-line basis over the estimated remaining development period.

 

We periodically review the expected performance periods under each of our agreements that provide for non-refundable up-front payments and license fees and milestone payments and the amortization periods are adjusted when appropriate.  Revenue recognition related to non-refundable license fees and up-front payments and to milestone payments could be accelerated in the event of early termination of programs or alternatively, decelerated, if programs are extended.

 

Cost of Revenue and Research and Development Expenses for Proprietary Drug Discovery

 

We incur costs in connection with performing research and development activities which consist mainly of compensation, associated fringe benefits, share-based compensation, preclinical and clinical outsourcing costs and other collaboration-related costs, including supplies, small tools, facilities, depreciation, recruiting and relocation costs and other direct and indirect chemical handling and laboratory support costs. We allocate these costs between Cost of Revenue and Research and Development Expenses for Proprietary Drug Discovery based upon the respective time spent on each by our scientists on our collaborations and for our internal proprietary programs. Cost of Revenue represents the costs associated with research and development, including preclinical and clinical trials, conducted by us for our collaborators. Research and Development Expenses for Proprietary Drug Discovery consist of direct and indirect costs related to specific proprietary programs and related to programs under collaboration agreements which we have concluded we are likely to retain the rights to. We do not bear any risk of failure for performing these activities and the payments are not contingent on the success or failure of the research program. Accordingly, we expense these costs when incurred.

 

33



Table of Contents

 

Where our collaboration agreements provide for us to conduct development of drug candidates, and for which our partner has an option to obtain the right to conduct further development and to commercialize a product, we attribute a portion of its research and development costs to Cost of Revenue based on the percentage of total programs under the agreement that we conclude is likely to be selected by the partner. These costs may not be incurred equally across all programs. In addition, we continually evaluate the progress of development activities under these agreements and if events or circumstances change in future periods that we reasonably believe would make it unlikely that a collaborator would exercise an option with respect to the same percentage of programs, we will adjust the allocation accordingly.

 

For example, we granted Celgene Corporation an option to select up to two of four programs developed under our collaboration agreement with Celgene and concluded that Celgene was likely to exercise its option with respect to two of the four programs. Accordingly, we reported costs associated with the Celgene collaboration as follows: 50% to Cost of Revenue, with the remaining 50% to Research and Development Expenses for Proprietary Drug Discovery through September 30, 2009, when Celgene waived its rights with respect to one of the programs during the second quarter of fiscal 2010, at which time, management determined that Celgene is likely to exercise its option to license one of the remaining three programs.  Accordingly, beginning October 1, 2009, we began reporting costs associated with the Celgene collaboration as follows: 33.3% to Cost of Revenue, with the remaining 66.7% to Research and Development Expenses for Proprietary Drug Discovery beginning October 1, 2009.   See Note 4, “Deferred Revenue,” for further information about the Company’s collaboration with Celgene.

 

Results of Operations

 

Revenue

 

Collaboration Revenue consists of revenue for our drug discovery and development efforts, which include: performance of drug discovery and development activities in collaboration with partners, as well as the sale of chemical compounds. License and Milestone Revenue are combined and consists of up-front license fees and ongoing milestone payments from collaborators.

 

A summary of our revenue follows (dollars in thousands):

 

 

 

Three Months Ended
December 31,

 

Change 2009 vs.
2008

 

Six Months Ended
December 31,

 

Change 2009 vs.
2008

 

 

 

2009

 

2008

 

$

 

%

 

2009

 

2008

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration revenue

 

$

4,434

 

$

5,041

 

$

(607)

 

(12.0%)

 

$

9,478

 

$

9,278

 

$

200

 

2.2

%

License and milestone revenue

 

5,210

 

2,648

 

2,562

 

96.8%

 

8,056

 

4,158

 

3,898

 

93.7

%

Total revenue

 

$

9,644

 

$

7,689

 

$

1,955

 

25.4%

 

$

17,534

 

$

13,436

 

$

4,098

 

30.5

%

 

The decrease in Collaboration Revenue of $607 thousand, or 12%, in the three months ended December 31, 2009 was attributable to fewer full time equivalent scientists (“FTE”) working on the Genentech collaboration as compared to the same period in the prior year.  This decrease was partially offset by an increase in the contracted rate per FTE.  Additionally, we earned approximately $400 thousand of revenue in fiscal 2009 from our now expired collaborations with VentiRx and AstraZeneca.  The increase during the six months ended December 31, 2009 related to additional revenue associated with the increased FTE rates noted above, of which approximately $650 thousand recorded in the first quarter of fiscal 2010 was non-recurring as it related to finalization of contract rates for services rendered in the prior fiscal year.  This increase was offset by fewer scientists engaged on the Genentech program and a $175 thousand decrease in revenue from our collaboration with VentiRx which ended in September 2009.

 

For the three and six months ended December 31, 2009 and 2008, License and Milestone Revenue increased $2.6 million and $3.9 million, respectively, over the same period in the prior year.  The increase

 

34



Table of Contents

 

during the three months ended December 31, 2009 includes $2.6 million in additional revenue recognized from the Celgene collaboration due to shortening the estimated period we expect to perform discovery research under the agreement from previously five more years to currently two more years.  Also, $903 thousand of revenue was recorded from the new collaboration agreement with Amgen as discussed further in Note 4 “Deferred Revenue” in the accompanying Condensed Financial Statements.  These increases during the current quarter were offset by the $1 million milestone we received in the second quarter of fiscal 2009 from VentiRx, which did not recur.  The increase during the six months ended December 31, 2009 was the result of the items noted above plus a $1 million milestone received in the first quarter of fiscal 2010 from InterMune for the advancement of ITNM-191 into Phase 2b clinical trials, which also did not recur.

 

Cost of Revenue

 

Cost of Revenue represents costs attributable to discovery and development including preclinical and clinical trials we may conduct for our collaborators and the cost of chemical compounds sold from our inventory. These costs consist mainly of compensation, associated fringe benefits, share-based compensation, preclinical and clinical outsourcing costs and other collaboration-related costs, including supplies, small tools, travel and meals, facilities, depreciation, recruiting and relocation costs and other direct and indirect chemical handling and laboratory support costs.

 

A summary of our Cost of Revenue follows (dollars in thousands):

 

 

 

Three Months Ended
December 31,

 

Change 2009 vs.
2008

 

Six Months Ended
December 31,

 

Change 2009 vs.
2008

 

 

 

2009

 

2008

 

$

 

%

 

2009

 

2008

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

$         5,235

 

$        5,063

 

$          172

 

3.4%

 

$       11,157

 

$      10,183

 

$          974

 

9.6%

 

Cost of revenue as a percentage of total revenue

 

54.3%

 

65.8%

 

 

 

 

 

63.6%

 

75.8%

 

 

 

 

 

 

Cost of Revenue increased in absolute dollars and decreased as a percentage of total revenue for the three and six months ended December 31, 2009 as compared to the same periods in the prior year.  The increase in absolute dollars is related to increased preclinical and clinical outsourcing costs for the advancement of certain collaboration programs, including Celgene and our new program with Amgen.  These increases were offset by the changed allocation methodology for Celgene costs from 50% to Cost of Revenue and 50% to Research and Development Expenses for Proprietary Drug Discovery to 33.3% and 67.7%, respectively as discussed further in Note 4 “Deferred Revenue” to the accompanying Condensed Financial Statements, as well as fewer scientists engaged on our collaboration with Genentech and the expiration of our collaboration with VentiRx.  The decrease as a percentage of total revenue was related to the increase in the license revenue recognized under the Celgene agreement and the catch up of prior year Genentech revenue that had no associated incremental costs, as discussed above.

 

Research and Development Expenses for Proprietary Drug Discovery

 

Our research and development expenses for proprietary drug discovery include costs associated with our proprietary drug programs for scientific and clinical personnel, supplies, inventory, equipment, small tools, travel and meals, depreciation, consultants, sponsored research, allocated facility costs, costs related to preclinical and clinical trials, and share-based compensation. We manage our proprietary programs based on scientific data and achievement of research plan goals. Our scientists record their time to specific projects when possible; however, many activities simultaneously benefit multiple projects and cannot be readily attributed to a specific project. Accordingly, the accurate assignment of time and costs

 

35



Table of Contents

 

to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on a program basis.

 

The following table shows our research and development expenses by categories of costs for the periods presented (dollars in thousands):

 

 

 

Three Months Ended
December 31,

 

Change 2009 vs.
2008

 

Six Months Ended
December 31,

 

Change 2009 vs.
2008

 

 

 

2009

 

2008

 

$

 

%

 

2009

 

2008

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, benefits and share-based compensation

 

$       8,205

 

$      9,938

 

$    (1,733)

 

(17.4%)

 

$     15,879

 

$   19,913

 

$    (4,034)

 

(20.3%)

 

Outsourced services and consulting

 

4,846

 

7,882

 

(3,036)

 

(38.5%)

 

10,724

 

15,925

 

(5,201)

 

(32.7%)

 

Laboratory supplies

 

2,992

 

2,710

 

282

 

10.4%

 

5,777

 

6,004

 

(227)

 

(3.8%)

 

Facilities and depreciation

 

2,646

 

2,619

 

27

 

1.0%

 

5,167

 

5,271

 

(104)

 

(2.0%)

 

Other

 

415

 

560

 

(145)

 

(25.9%)

 

758

 

1,105

 

(347)

 

(31.4%)

 

Total research and development for proprietary drug discovery

 

$     19,104

 

$    23,709

 

$    (4,605)

 

(19.4%)

 

$     38,305

 

$   48,218

 

$    (9,913)

 

(20.6%)

 

 

Research and Development Expenses for Proprietary Drug Discovery for the three and six months ended December 31, 2009 decreased from the prior year due to shifting our development efforts towards our most advanced programs and reduced resources devoted to early discovery research, which occurred after the second quarter of fiscal 2009. We believe our spending on research and development for our proprietary programs will continue to trend down during fiscal 2010 because of the recent collaboration with Amgen which will cause our development costs for AMG 151 / ARRY-403 to shift to Amgen and based on the success of partnering additional programs in the future.

 

General and Administrative Expenses

 

General and Administrative Expenses consist mainly of compensation and associated fringe benefits not included in Cost of Revenue or Research and Development Expenses for Proprietary Drug Discovery and include other management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting and relocation, consulting and professional services, travel and meals, sales commissions, facilities, depreciation and other office expenses.

 

A summary of our General and Administrative Expenses follows (dollars in thousands):

 

 

 

Three Months Ended December 31,

 

Change 2009 vs.
2008

 

Six Months Ended December 31,

 

Change 2009 vs.
2008

 

 

 

2009

 

2008

 

$

 

%

 

2009

 

2008

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

$       4,460

 

$      4,480

 

$          (20)

 

(0.4%)

 

$       8,673

 

$      8,974

 

$        (301)

 

(3.4%)

 

 

General and Administrative Expenses remained relatively consistent between three and six months ended December 31, 2009 and 2008, respectively.  During the six month period, there were increased employee compensation expenses due to employee raises and share based compensation, and increased professional fees due to costs related to the new collaboration agreement with Amgen Inc., ongoing licensing efforts and the valuation of our Embedded Derivatives. These increased costs were offset by reduced patent filing costs and reduced software and license fees.

 

36



Table of Contents

 

Other Income (Expense)

 

A summary of our Other Income (Expense) follows (dollars in thousands):

 

 

 

Three Months Ended
December 31,

 

Change 2009 vs.
2008

 

Six Months Ended
December 31,

 

Change 2009 vs.
2008

 

 

 

2009

 

2008

 

$

 

%

 

2009

 

2008

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Impairment of marketable securities

 

$              -

 

$  (10,452)

 

$    10,452

 

0.0%    

 

$       (217)

 

$  (14,362)

 

$    14,145

 

0.0%   

 

Interest income

 

1,422

 

533

 

889

 

166.8%

 

1,726

 

1,413

 

313

 

22.2%

 

Interest expense

 

(4,092)

 

(2,336)

 

(1,756)

 

75.2%

 

(7,534)

 

(4,616)

 

(2,918)

 

63.2%

 

Total other income (expense)

 

$    (2,670)

 

$  (12,255)

 

$      9,585

 

(78.2%)

 

$    (6,025)

 

$  (17,565)

 

$    11,540

 

(65.7%)

 

 

The impairment charges for our ARS were recorded as shown in the table above as a result of our conclusion that the decline in value of our ARS was other-than-temporary.  We recognized $10.5 million in impairment charges during the three months ended December 31, 2008.  We recognized $217 thousand and $14.4 million during the six months ended December 31, 2009 and 2008, respectively.  See Note 3 “Marketable Securities” in the accompanying Condensed Financial Statements for further information on our ARS.

 

Interest Income increased during the second quarter and first half of fiscal 2010 as compared to the same periods in fiscal 2009 primarily due to the sale of an ARS with a par value of $4 million.  We recognized a gain of $1.2 million, of which $394 thousand was reclassified from Accumulated Other Comprehensive Income to earnings.  This gain was offset by lower effective interest rates and lower average cash, cash equivalent and marketable security balances.

 

Interest Expense increased in the second quarter and first half of fiscal 2010 compared to the same periods in fiscal 2009 due to increased borrowings under the Deerfield credit facilities.

 

The following table presents the components of Interest Expense for the three and six months ended December 31, 2009 and 2008 (dollars in thousands):

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

December 31,

 

December 31,

 

 

 

2009

 

2008

 

2009

 

2008

 

 

 

 

 

 

 

 

 

 

 

Deerfield Credit Facility:

 

 

 

 

 

 

 

 

 

2.0% simple interest

 

$            -      

 

$           (403)

 

$           (124)

 

$           (807)

 

6.5% compounding interest

 

-      

 

(1,347)

 

(476)

 

(2,672)

 

7.5% simple interest

 

(2,250)

 

-     

 

(3,750)

 

-     

 

Amortization of the transaction fees

 

(143)